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Abstract
AIM: To evaluate the effect of gastrectomy on diabe-
tes control in patients with type 2 diabetes mellitus and 
early gastric cancer.
METHODS: Data from 64 patients with early gastric 
cancer and type 2 diabetes mellitus were prospectively 
collected. All patients underwent curative gastrectomy 
(36 subtotal gastrectomy with gastroduodenostomy, 16 
subtotal gastrectomy with gastrojejunostomy, 12 total 
gastrectomy) and their physical and laboratory data 
were evaluated before and 3, 6 and 12 mo after sur-
gery.
RESULTS: Fasting blood glucose (FBS), HbA1c, insulin, 
C-peptide, and homeostasis model assessment-esti-
mated insulin resistance were significantly improved 3 
mo after surgery, regardless of operation type, and the 
significant improvement in all measured values, except 
HbA1c, was sustained up to 12 mo postoperatively. Ap-
proximately 3.1% of patients stopped diabetes medi-
cation and had HbA1c < 6.0% and FBS < 126 mg/dL. 
54.7% of patients decreased their medication, and had 
reduced FBS or HbA1c. In multivariate analysis, good 
diabetic control was not associated with operation type, 
but was associated with diabetes duration. 
CONCLUSION: Diabetes improved in more than 50% 
of patients during the first year after gastric cancer 
surgery. The degree of diabetes control was related to 
diabetes duration. 
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Diabetes mellitus is one of the most important 
health problems and has an impact on the quality of life 
of gastric cancer patients as well as ordinary individu-
als. In this study, we evaluated the impact of conven-
tional gastric cancer surgery on type 2 diabetes. Gastric 
cancer surgery led to a significant improvement in type 
2 diabetes during the first year after surgery, and the 
degree of diabetes control was related to diabetes du-
ration.
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INTRODUCTION
Gastric cancer is a leading cause of  cancer death world-
wide and is one of  the most common cancers in Ko-
rea[1,2]. During the last several decades, there has been 
notable progress in the field of  gastric cancer diagnosis 
and treatment, as indicated by the increasing proportion 
of  early gastric cancers and improved survival rate[3,4]. 
Therefore, postoperative quality of  life as well as the ap-
propriate surgical treatment for a cure has become very 
important. 
However, the increase in older patients due to an ag-
ing population and the increased incidence of  lifestyle-
related diseases including diabetes, hypertension, car-
diovascular disease, and hypercholesterolemia make 
postoperative healthcare more difficult and complicated. 
Diabetes mellitus (DM) is one of  the most difficult health 
problems worldwide as it is a multi-factorial chronic dis-
ease. In Korea, the prevalence of  diabetes has increased 
dramatically from less than 1.5% in the 1970s to approxi-
mately 10% in the 2000s, and it is currently the 5th most 
common cause of  death[5,6]. Although the prevalence of  
diabetes in gastric cancer patients has not been reported, 
it may be similar to that of  the general population. After 
gastric cancer surgery, many surgeons focus on improv-
ing the nutritional status of  patients rather than control-
ling diabetes as the main problem after gastric cancer sur-
gery is weight loss. In addition, the beneficial effects of  
weight loss often lead to improvement in hyperglycemia, 
hypercholesterolemia, and hypertension. 
Recently, metabolic surgery has become an appealing 
treatment option for patients with type 2 DM. The ef-
fects of  metabolic surgery and the mechanism of  action 
have been reported in several studies[7-9]. Although the 
purpose of  metabolic surgery and gastric cancer surgery 
is completely different, there is a connection between the 
two procedures clinically and technically. In line with this 
thinking, the organized evaluation of  the impact of  con-
ventional gastric cancer surgery on diabetes appears to be 
necessary. Such an evaluation will allow surgeons to select 
a favorable reconstruction type after gastrectomy in gas-
tric cancer patients with diabetes. Therefore, in this study, 
we investigated the short-term effect of  three types of  
routine gastric cancer surgery on type 2 DM. 
MATERIALS AND METHODS
Patients
We analyzed the data from 64 early gastric cancer patients 
with type 2 DM who underwent curative gastrectomy for 
primary gastric cancer between 2009 and 2010. All of  
the patients had been diagnosed with type 2 DM after 40 
years of  age and were taking medication before the diag-
nosis of  early gastric cancer. All the data were collected 
prospectively. Patients with the following conditions 
were excluded: (1) other malignancies; (2) pre- and post-
operative chemotherapy or chemoradiotherapy; (3) other 
endocrine disorders such as thyroid or adrenal disease; 
(4) moderate to severe cardiovascular, pulmonary or renal 
disease; and (5) active infection. This study was reviewed 
and approved by the Institutional Review Board of  Sev-
erance Hospital, Yonsei University College of  Medicine, 
and written informed consent was obtained from all pa-
tients prior to surgery.
Surgical procedures
Subtotal or total gastrectomy was performed according 
to the tumor location. Billroth Ⅰ or Ⅱ reconstruction 
was carried out after subtotal gastrectomy and Roux-
en-Y esophagojejunostomy after total gastrectomy. In 
Billroth  Ⅰ reconstruction, the duodenum was transected 
1 cm distal to the pyloric ring and gastroduodenostomy 
was performed using a circular stapler. In Billroth Ⅱ 
reconstruction, the length from the ligament of  Treitz 
was approximately 20 cm and gastrojejunostomy was per-
formed using a linear stapler. After total gastrectomy, the 
length of  the esophagojejunostomy to jejunojejunostomy 
was approximately 45 cm, and the length of  the ligament 
of  Treitz to jejunojejunostomy was 20-25 cm. Esoph-
agojejunostomy was performed using a circular stapler. 
Generally, D1+β or D2 lymph node dissection was per-
formed according to the guidelines of  the Japanese Gas-
tric Cancer Association[10]. 
Evaluation of clinical variables and biochemical data 
during follow-up
All of  the clinical and laboratory data were collected 
and recorded prospectively at each point of  the routine 
follow-up. Blood samples were obtained after an over-
night fast. Patients visited the hospital at 3-, 6- and 12-mo 
time points during the first year after gastrectomy for a 
physical examination, laboratory tests, imaging, and/or 
endoscopy. The variables for evaluating the status of  
glucose control included body weight, body mass index, 
biochemical data [serum glucose, HbA1c, insulin, C-pep-
tide, homeostasis model assessment-estimated insulin 
resistance (HOMA-IR), low-density lipoprotein (LDL)-
cholesterol, high-density lipoprotein (HDL)-cholesterol, 
triglyceride], and medication status, and were recorded 
preoperatively and 3, 6 and 12 mo after surgery. All of  
the patients completed the study.
The degree of  diabetes control was divided into 
three groups: (1) Remission: No medication and FBS < 
126 mg/dL and HbA1c < 6.0%; (2) Improved: Reduced 
medication and one of  the following: FBS or HbA1c 
reduction; and (3) Stationary: No change of  medication, 
or patients excluded from the improved and remission 
categories.
Statistical analysis
Statistical analysis was carried out using SPSS® version 
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15.0 for Windows® (SPSS, Chicago, IL, United States). 
Categorical variables were compared using the chi-square 
or Fisher exact test, and continuous data were compared 
by the Mann-Whitney U test. The Kruskal-Wallis test 
was used to compare biochemical data among the three 
surgical groups at the same evaluation time. The paired t 
test was used to compare preoperative and postoperative 
12-mo biochemical data. Data are presented as mean ± 
SD. Binary logistic regression analysis was used to iden-
tify the independent variables associated with the degree 
of  diabetic control. P values < 0.05 were considered sta-
tistically significant.
RESULTS
Patient demographics
The preoperative patient demographics are shown in 
Table 1. The mean body mass index (BMI) was 24.7 ± 3.4 
kg/m2. After subtotal gastrectomy, gastroduodenostomy 
(STG BⅠ) was performed in 36 patients and gastroje-
junostomy (STG BⅡ) in 16 patients. Twelve patients 
underwent total gastrectomy with Roux-en-Y esophago-
jejunostomy (TG). Of  the patients in this study, 18.8% 
had a family history of  diabetes in first degree relatives, 
93.7% were taking oral hyperglycemic agents, and 6.3% 
were taking insulin with or without oral agents. 
Changes in biochemical data after surgery
All of  the patients completed 12-mo follow-up. BMI, 
FBS, HbA1c, insulin, C-peptide, HOMA-IR, triglyceride, 
LDL-cholesterol, and HDL-cholesterol were determined 
preoperatively and 3, 6 and 12 mo after surgery (Table 2). 
In the same operation type, data on preoperative day 
and postoperative 12 mo were compared. In addition, at 
the same follow-up points, variables of  each operation 
type were compared. Figure 1 shows the changes in mean 
value of  the biochemical data. BMI rapidly decreased 
during the first 3 mo after surgery and was maintained up 
to 12 mo (Figure 1A). In all operation types, the 12-mo 
postoperative BMI value significantly decreased to ap-
proximately 90% of  the preoperative value. At the same 
follow-up point, BMI level showed no significant differ-
ence according to operation type. Despite this, the degree 
of  weight loss tended to be greater after total gastrec-
tomy than after subtotal gastrectomy. 
The FBS levels at 3, 6 and 12 mo after surgery were 
lower than preoperative levels, and the difference in FBS 
levels at the preoperative time point and 12 mo after STG 
BⅠ (P = 0.001) was statistically significant. As shown in 
Figure 1B, FBS levels decreased markedly up to 3 or 6 
mo after surgery and then slowly declined or increased 
again up to 12 mo. There was no difference in the FBS 
level according to operation type at the same time points. 
HbA1c levels improved 3 mo after each type of  
surgery, but increased 12 mo after subtotal gastrectomy 
and were maintained after total gastrectomy (Figure 1C). 
Therefore, there were no significant differences between 
preoperative and postoperative 12-mo HbA1c levels fol-
lowing the three types of  surgery. This may be associated 
with the stabilization of  BMI and FBS levels between 
3 and 12 mo after surgery, which would result from an 
increase in food intake. Insulin levels rapidly decreased 3 
mo after all types of  surgery and then slowly decreased 
up to 12 mo (Figure 1D). 
There were significant differences in insulin and 
C-peptide levels (Figure 1E) between 3 and 12 mo after 
surgery, but there were no differences according to op-
eration type at the same follow-up points. HOMA-IR 
levels consistently improved at 3, 6 and 12 mo after all 
types of  surgery (Figure 1F) and the levels at 12 mo after 
surgery were significantly lower than the preoperative 
levels. The HOMA-IR level at 6 mo follow-up after total 
gastrectomy was significantly lower than that after subto-
tal gastrectomy.
The lipid profile which included triglyceride, LDL, 
and HDL did not show significant differences between 
preoperative and postoperative 12-mo levels, with the 
exception of  HDL level in the STG BⅠ group (Figure 
1G-I).
Diabetes control after surgery
Patients were divided into three groups based on their 
diabetes status: stationary, improved and remission (Table 
3). Among the 64 patients, 35 patients (54.7%) improved 
and 2 patients (3.1%) went into remission. In the STG B
Ⅰ group, 58.3% of  patients had improved 12 mo after 
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Table 1  Patient demographics  n  (%)
Variables n  = 64
Age (yr) 62.7 ± 8.6
Range 45-77
Sex 
   Male 43 (67.2)
   Female 21 (32.8)
Body mass index (kg/m2) 24.7 ± 3.4
Range 18.6-38.1
Smoking history 
   No 36 (56.2)
   Yes 28 (43.8)
Alcohol history
   No 38 (59.4)
   Yes 26 (40.6)
Family history of DM 
   No 52 (81.2)
   Yes 12 (18.8)
Operation type
   STG BⅠ 36 (56.2)
   STG BⅡ 16 (25.0)
   TG 12 (18.8)
Surgical approach 
   Open surgery 28 (43.7)
   Laparoscopic surgery 36 (56.3)
Duration of DM (yr) 6.6 ± 6.4
Range 0.5-25
DM medication 
   Oral hyperglycemic agents 60 (93.7)
   Insulin only 1 (1.6)
   Both 3 (4.7)
Data are expressed as absolute numbers (percentage) or mean ± SD. 
DM: Diabetes mellitus; STG BⅠ: Subtotal gastrectomy with Billroth I 
anastomosis; STG BⅡ: Subtotal gastrectomy with Billroth Ⅱ anastomosis; 
TG: Total gastrectomy. 
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Postoperative BMI changes, smoking history, and the du-
ration of  type 2 DM were predictive factors for diabetes 
control after surgery. BMI levels 3-, 6- and 12-mo after 
surgery were lower, the incidence of  non-smokers was 
higher, and the duration of  DM was shorter in patients 
satisfying improved or remission criteria than those in the 
stationary group. 
In multivariate analysis, the duration of  DM was the 
only significant factor associated with postoperative dia-
betic control (Table 5). 
DISCUSSION
In recent studies which evaluated diabetes resolution after 
gastric cancer surgery, diabetes remitted in 15.1%-19.7% 
of  gastric cancer patients[11,12]. However, because these 
studies involved a retrospective review of  medical re-
surgery and 16.7% of  patients stopped their medication. 
However, no patients went into remission. In the STG B
Ⅱ group, one (6.2%) of  16 patients went into remission 
and 9 (56.2%) were improved 12 mo after surgery. In the 
TG group, 5 (41.7%) patients were improved and one 
(8.3%) was in remission 12 mo after surgery. Three (25%) 
patients stopped medication. 
Factors for diabetes control 12 mo after surgery
We compared the improved and in remission patients to 
those who were stationary to identify predictive factors 
for diabetes control. Age, sex, change in BMI, smoking, 
alcohol history, familial history (1st degree relatives) of  
type 2 DM, operation type, preoperative fasting blood 
glucose, HbA1c, insulin, C-peptide, HOMA-IR, triglycer-
ide, LDL, and HDL were not associated with the degree 
of  diabetes control 12 mo after gastrectomy (Table 4). 
Table 2  Changes in biochemical data after surgery according to the follow up period and operation type
Operation type Preoperative PO 3 mo PO 6 mo PO 12 mo 1P  pre-12 mo
BMI (kg/m2) STG BI 24.3 ± 2.9 22.5 ± 2.6 22.3 ± 2.8 21.9 ± 2.7 < 0.001
STG BⅡ 24.7 ± 3.1 22.6 ± 2.9 22.9 ± 2.1 22.1 ± 1.9 0.002
TG 25.7 ± 5.2 23.8 ± 5.7 22.5 ± 4.6 22.9 ± 4.4 0.004
2P 0.793 0.965 0.616 0.780
BMI STG BⅠ 100% 92.9% ± 5.2% 92.2% ± 5.3% 92.0% ± 7.0% < 0.001
STG BⅡ 100% 91.6% ± 6.7% 93.3% ± 6.9% 90.3% ± 11.0% 0.004
TG 100% 90.9% ± 6.4% 87.8% ± 5.7% 87.1% ± 8.1% 0.003
2P    1.000 0.661 0.050 0.333
Glucose (mg/dL) STG BⅠ 147.3 ± 44.1 125.0 ± 30.3 122.3 ± 38.4 114.4 ± 21.7 0.001
STG BⅡ 155.7 ± 40.0 136.4 ± 56.6 122.5 ± 31.9 126.4 ± 39.1 0.061
TG 145.9 ± 37.5 114.3 ± 22.2 117.0 ± 28.0 115.4 ± 27.3 0.234
2P 0.682 0.489 0.931 0.773
HbA1c STG BⅠ 7.2% ± 1.1% 6.8% ± 0.6% 7.0% ± 0.7% 7.1% ± 0.9% 0.834
STG BⅡ 7.3% ± 1.3% 6.9% ± 1.4% 7.1% ± 1.3% 7.1% ± 1.6% 0.626
TG 7.1% ± 0.8% 6.5% ± 0.7% 6.5% ± 0.5% 6.5% ± 0.6% 0.119
2P 0.981 0.227 0.201 0.201
Insulin (μIU/mL) STG BⅠ 21.3 ± 20.7 8.6 ± 11.2 8.1 ± 11.3 5.1 ± 4.7 < 0.001
STG BⅡ 22.5 ± 29.0 9.6 ± 8.8 8.9 ± 3.5 7.7 ± 7.1 0.041
TG 18.1 ± 10.1 7.5 ± 5.7 4.0 ± 2.1 3.7 ± 1.9 0.02
2P 0.679 0.652 0.050 0.350
C-peptide (ng/mL) STG BⅠ 3.4 ± 2.3 2.1 ± 1.6 2.3 ± 1.2 1.5 ± 0.8 < 0.001
STG BⅡ 3.3 ± 1.8 2.0 ± 1.4 2.4 ± 0.9 2.1 ± 1.5 0.028
TG 2.8 ± 1.3 2.1 ± 1.2 1.5 ± 1.3 1.6 ± 0.6 0.02
2P 0.877 0.778 0.597 0.523
HOMA-IR STG BⅠ 8.7 ± 10.1 2.9 ± 4.7 2.6 ± 7.9 1.3 ± 0.9 0.001
STG BⅡ 9.3 ± 13.5 3.3 ± 3.4 2.9 ± 2.0 2.5 ± 2.5 0.045
TG 7.1 ± 4.1 2.1 ± 1.6 0.8 ± 0.2 1.1 ± 0.6 0.015
2P 0.660 0.484 0.036 0.176
TG (mg/dL) STG BⅠ 126.1 ± 80.8 100.1 ± 51.6 115.9 ± 62.6 101.4 ± 41.7 0.341
STG BⅡ 144.8 ± 102.6 118.5 ± 75.9 124.3 ± 53.7 105.2 ± 44.6 0.114
TG 143.5 ± 88.9 130.5 ± 71.4 72.3 ± 36.6 96.6 ± 37.3 0.082
2P 0.831 0.503 0.130 0.937
LDL (mg/dL) STG BⅠ 96.8 ± 34.7 89.0 ± 27.9 81.3 ± 23.5 90.8 ± 29.2 0.522
STG BⅡ 97.4 ± 28.7 97.9 ± 33.5 94.4 ± 29.7 101.6 ± 37.5 0.515
TG 113.6 ± 28.9 99.8 ± 28.0 63.5 ± 32.0 98.5 ± 32.0 0.023
2P 0.299 0.556 0.192 0.594
HDL (mg/dL) STG BⅠ 43.9 ± 10.6 48.3 ± 11.4 49.4 ± 15.1 52.0 ± 15.1 0.002
STG BⅡ 43.2 ± 9.2 42.6 ± 8.2 46.2 ± 10.6 46.5 ± 8.6 0.173
TG 42.4 ± 10.5 45.0 ± 7.3 48.7 ± 3.2 46.3 ± 8.1 0.073
2P 0.953 0.161 0.757 0.552
1Paired t-test, mean ± SD; 2Kruskal-Wallis test was used to evaluate the difference by operation type at the same follow up period. Significant values are 
indicated in bold face. BMI: Body mass index, BMI (%) refers to percentage of BMI at each follow-up compared to preoperative BMI. STG BⅠ: Subtotal 
gastrectomy with Billroth Ⅰ anastomosis; STG BⅡ: Subtotal gastrectomy with Billroth Ⅱ anastomosis; TG: Total gastrectomy; HOMA-IR: Homeostasis 
model assessment-estimated insulin resistance; LDL: Low-density lipoprotein; HDL: High-density lipoprotein. 
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cords or interviewing, the available laboratory and physi-
cal parameters were limited. Although data analysis of  
the present study was performed retrospectively, all of  
our data were collected prospectively including laboratory 
data, body weight change, medical and familial history, 
and medication status. The low rate of  diabetic remission 
in our study (3.1%) may be due to the strict evaluation of  
parameters reflecting diabetic control status at an exact 
time point, 12 mo after surgery. 
The BMI of  patients decreased by approximately 
10% in the first 3 mo after surgery and was maintained 
or slightly decreased until the 12-mo evaluation. The FBS 
level showed rapid improvement at 3 mo and then slowed 
or was maintained up to 12 mo. HbA1c levels decreased 
at 3 mo and then increased or maintained between 3 and 
12 mo after surgery. These patterns were similar in all 
three types of  surgery and may be associated with the 
increased calorie intake and general recovery that occurs 
3 mo after gastrectomy. These results suggest that weight 
loss is an important factor for diabetes improvement af-
ter gastric cancer surgery. Because one of  the main treat-
ments for type 2 diabetes is reduced calorie intake and 
gastrectomy is a type of  restrictive surgery, our results are 
not unexpected[13]. 
However, serum insulin, C-peptide, and HOMA-IR 
continuously improved to at least 12 mo after surgery, 
even if  the rate of  improvement slowed 3 mo post-
operatively. As shown in Table 2 and Figure 1, insulin, 
C-peptide, and HOMA-IR levels were significantly lower 
at the 12-mo evaluation compared to preoperative levels 
in all operation types. This suggests that insulin resis-
tance continued to improve after surgery up to 12 mo, 
although body weight, FBS, and HbA1c did not. Gastric 
cancer surgery, including gastric resection with or without 
bypass procedures of  a short segment of  the proximal 
small bowel, appears to have a beneficial metabolic influ-
ence on diabetes control. However, considering that the 
pattern of  biochemical data was similar in the STG B
Ⅰ and STG BⅡ group, incomplete bypass of  a short 
segment of  proximal small bowel (BⅡ) did not seem to 
provide significant additional benefits in terms of  glucose 
metabolism. 
The need for and amount of  diabetes medication, 
FBS levels, and HbA1c levels are convenient tools for 
evaluating the impact of  gastric cancer surgery on glu-
cose control in clinical practice. We divided patients into 
three groups (stationary, improved, and remission) based 
on the severity of  diabetes after surgery. Thirty three 
(51.6%) of  64 patients had improved glycemic control 3 
mo after surgery and this increased to 54.7% 12 mo after 
surgery. One patient went into remission 3 mo after STG 
BⅠ, however, this patient did not satisfy remission crite-
ria at the 12 mo evaluation time. Finally, only 2 patients 
were in remission 12 mo after surgery: one (6.2%) in the 
Table 3  Degree of diabetes mellitus control after surgery  n  (%)
STG BⅠ (n  = 36) STG BⅡ (n  = 16) TG (n  = 12)
3 mo 6 mo 12 mo 3 mo 6 mo 12 mo 3 mo 6 mo 12 mo
Stationary 16 (44.4) 16 (44.4) 15 (41.7) 8 (50) 8 (50)   6 (37.5) 6 (50) 7 (58.3) 6 (50)
Improved 19 (52.8) 20 (62.5) 21 (58.3) 8 (50) 8 (50)   9 (56.2) 6 (50)  4 (33.3)   5 (41.7)
Remission 1 (2.8) 0 0 0 0  1 (6.2) 0 1 (8.3) 1 (8.3)
Medication stopped   6 (16.7)   6 (16.7)   6 (16.7)   2 (12.5)    2 (12.5) 4 (25) 3 (25) 3 (25) 3 (25)
Stationary: No change in medication, or patients except improved and remission criteria; Improved: Reduced medication and a reduction in fasting blood 
glucose (FBS) or HbA1c; Remission: No medication and FBS < 126 mg/dL and HbA1c < 6.0%. STG BⅠ: Subtotal gastrectomy with Billroth Ⅰ anastomosis; 
STG BⅡ: Subtotal gastrectomy with Billroth Ⅱ anastomosis; TG: Total gastrectomy. 
Figure 1  Changes in body mass index and serum biochemical data after gastric cancer surgery according to the follow-up periods and operation type. A: 
Body mass index; B: Fasting blood glucose level; C: HbA1c; D: Insulin; E: C-peptide; F: Homeostasis model assessment-estimated insulin resistance; G: Triglyceride; H: 
Low-density lipoprotein-cholesterol; I: High-density lipoprotein-cholesterol. 
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STG BⅡ group and the other (8.3%) in the TG group. It 
seems to be difficult to adequately control diabetes with 
gastric cancer surgery to stop medication. 
As shown in Table 5, the predictive factor for dia-
betes control 12 mo after surgery was the duration of  
diabetes. In univariate analysis, the rate of  BMI change, 
smoking history, and diabetes duration were associated 
with diabetes control 12 mo after surgery. In multivariate 
analysis, diabetes was controlled in gastric patients with 
a shorter duration of  diabetes. This result was similar to 
previous reports of  type 2 DM patients who took oral 
hypoglycemic agents and for those who received bariatric 
surgery[14,15]. It is possible that islet cell function is less 
impaired in patients with a shorter duration of  diabetes 
than in patients with a longer duration. Therefore, dia-
betes control would be more effective in gastric cancer 
patients with a short history of  diabetes. The operation 
type which reflects the extent of  gastric resection and 
the presence of  bypass of  a short segment of  proximal 
jejunum, were not associated with diabetes control 12 
mo after surgery. Although we failed to identify a differ-
ence in the efficacy of  diabetes control based on the type 
of  gastric cancer surgery, we did find that gastric cancer 
surgery positively affected diabetes. Although only 3.1% 
of  the 64 patients went into remission, 57.8% showed 
improved glycemic control after surgery. Considering 
that approximately 10% of  the general population suffers 
from diabetes and the incidence of  diabetes in gastric 
cancer patients is similar to that of  the general popula-
tion, an improvement in diabetes after gastric cancer 
surgery would reduce health-care costs and improve the 
quality of  life of  these individuals. 
Because more than half  of  the patients in this study 
were not obese, the impact of  gastrectomy described 
should not be interpreted as if  resulting from bariatric 
surgery. This study was initially planned to help surgeons 
select the most effective gastric cancer surgery for gas-
tric cancer patients with diabetes. In other retrospective 
studies, diabetic resolution rates after TG ranged from 
27.3%-50%, which were much higher than those after 
STG BⅠ and BⅡ. However, because the pattern of  
clinical and laboratory data were similarly changed in all 
three groups, we could not identify a difference between 
the STG BⅠ and STG BⅡ groups or between the STG 
and TG groups. Considering that the gap in HbA1c, in-
sulin, C-peptide, and HOMA-IR levels between STG and 
TG widened at postoperative 6 mo, TG seemed to have 
more potential for better and more persistent glucose 
control than STG. However, they showed no significant 
difference at postoperative 12 mo and we cannot clarify 
whether the extent of  gastrectomy or bypass length was 
more important in this study. We did not include patients 
who had STG with Roux-en-Y reconstruction which can 
provide a longer and complete bypass length of  proxi-
mal jejunum than STG BⅠ and BⅡ. As the extent of  
gastrectomy mainly depends on the tumor location and 
extent, and the length of  bypass of  proximal small bowel 
is very short in conventional gastric cancer surgery, the 
Table 4  Factors for diabetic control at postoperative 12 mo 
n  (%)
Stationary 
(n  = 27)
Improved or 
remission (n  = 37)
1P  (univariate)
Age (yr) 64.3 ± 7.2 62.2 ± 8.4  0.5822
Sex 0.789
   Male 19 (44.2) 24 (55.8)
   Female   8 (38.1) 13 (61.9)
BMI, preop 
(kg/m2)
24.5 ± 4.0 24.9 ± 3.0  0.4342
BMI
   3 mo 94.4% ± 5.0% 91.2% ± 5.3%  0.0182
   6 mo 93.7% ± 6.8% 90.4% ± 5.7%  0.0362
   12 mo 93.8% ± 9.1% 88.9% ± 7.8%  0.0412
Smoking 0.043
   Yes 16 (57.1) 12 (42.9)
   No 11 (30.6) 25 (69.4)
Alcohol history 0.132
   No 13 (34.2) 25 (65.8)
   Yes 14 (53.8) 12 (46.2)
DM duration (yr) 0.013
   > 10 10 (76.9)   3 (23.1)  
   5-10   8 (40.0) 12 (60.0)
   < 5   9 (29.0) 22 (71.0)
Family history of DM 1.000
   No 22 (42.3) 30 (57.7)
   Yes   5 (41.7)   7 (58.3)
Operation type 0.799
   STG BⅠ 15 (41.7) 21 (58.3)
   STG BⅡ   6 (37.5) 10 (62.5)
   TG   6 (50.0)   6 (50.0)
Preop FBS 152.1 ± 43.6 145.6 ± 40.3 0.6242
Preop HbA1c   6.9 ± 0.8   7.4 ± 1.2 0.3132
Preop Insulin   21.7 ± 26.3   19.0 ± 17.8 0.8042
Preop C-peptide   3.1 ± 2.2   3.3 ± 1.9 0.5092
Preop HOMA-IR     9.2 ± 12.8   7.3 ± 8.0 0.8352
1 χ2; 2Mann-Whitney U test, mean ± SD. Significant values are indicated 
in bold face. BMI: Body mass index, BMI (%) refers to the percentage of 
BMI at postoperative follow-up. DM: Diabetes mellitus; STG BⅠ: Subtotal 
gastrectomy with Billroth Ⅰ anastomosis; STG BⅡ: Subtotal gastrectomy 
with Billroth Ⅱ anastomosis; TG: Total gastrectomy; FBS: Fasting blood 
glucose; HOMA-IR: Homeostasis model assessment-estimated insulin 
resistance.
Table 5  Multivariate analysis of predictive factors for diabetic 
control at postoperative 12 mo
Variables Odds ratio 95%CI 1P
Sex
   Male
   Female   0.168 0.018-1.529 0.113
Smoking
   Yes
   No 12.636     0.946-124.216 0.068
BMI (%) 
   3 mo   0.869 0.690-1.094 0.232
   6 mo   0.839 0.626-1.125 0.240
   12 mo   1.055 0.893-1.246 0.526
DM duration (yr)
   > 10
   5-10 27.505     2.174-347.988 0.010
   < 5 10.583     0.808-138.670 0.072
Operation type
   STG BⅠ
   STG BⅡ   0.547 0.086-3.493 0.523
   TG   0.088 0.006-1.365 0.088
1Binary logistic regression. STG BⅠ: Subtotal gastrectomy with Billroth Ⅰ an-
astomosis; STG BⅡ: Subtotal gastrectomy with Billroth Ⅱ anastomosis; TG: 
Total gastrectomy. 
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modification of  bypass length of  proximal small bowel 
would offer a better outcome for diabetic control. There-
fore, a study that includes a larger number of  patients 
and other types of  surgery will be necessary to identify 
any differences between the types of  gastric cancer sur-
gery. In addition, we did not determine postprandial glu-
cose and insulin level, thus we calculated only the insulin 
sensitivity index using a fasting-based formula. Therefore, 
further studies are needed to investigate the effect of  
gastric cancer surgery on gastric cancer patients with type 
2 DM using an insulin sensitivity index derived from the 
oral glucose tolerance test. 
In conclusion, gastric cancer surgery led to weight 
loss and a significant improvement in type 2 DM during 
the first year after surgery. The degree of  diabetes control 
was related to diabetes duration in each patient. However, 
the impact of  operation type in conventional gastric can-
cer surgery, such as the extent of  gastric resection and 
current reconstruction methods, on diabetes remains to 
be determined. 
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